Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.

Helicobacter·2026
Same author

Sex and Gender Differences in Peptic Ulcer Disease: A Scoping Review with Exploratory Quantitative Synthesis for Clinical Guideline Development.

Gut and liver·2026
Same author

Prevalence of Autoimmune Diseases in Individuals Living with HIV in Korea: A Nationwide Population-Based Study.

Medicina (Kaunas, Lithuania)·2026
Same author

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

Gut and liver·2026
Same author

Liver Failure versus Organ Failure in Acute-on-Chronic Liver Failure: Sequence and Consequence.

Gut and liver·2026
Same author

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB.

Journal of gastroenterology and hepatology·2026

Related Experiment Video

Updated: Jul 16, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

MIT-001, a Mitochondria-Targeted ROS Scavenger, Ameliorates DSS-Induced Colitis and Is Associated with Reduced HMGB1

Dongwoo Kim1,2, Soon Ha Kim3, Jung Wan Choe1,2

  • 1Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.

International Journal of Molecular Sciences
|July 15, 2026
PubMed
Summary

MIT-001, a novel anti-necrotic drug, reduced intestinal inflammation and injury in a preclinical model of inflammatory bowel disease (IBD). This suggests targeting cell death pathways may offer new therapeutic strategies for IBD patients.

Keywords:
HMGB1MIT-001inflammatory bowel diseasemitochondrial reactive oxygen speciesnecrosisulcerative colitis

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jul 16, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Area of Science:

  • Gastroenterology
  • Cell Biology
  • Pharmacology

Background:

  • Inflammatory bowel disease (IBD) involves chronic intestinal inflammation.
  • Excessive cell death and damage-associated molecular patterns (DAMPs) like HMGB1 worsen mucosal injury in IBD.
  • Targeting necrotic cell death, including necroptosis and ferroptosis, is a potential therapeutic avenue for IBD.

Purpose of the Study:

  • To investigate if MIT-001, a mitochondria-targeted reactive oxygen species (ROS) scavenger with anti-necrotic activity, can alleviate intestinal inflammation in a dextran sulfate sodium (DSS)-induced colitis model.
  • To assess MIT-001's effects on cell death markers and inflammatory mediators in vitro and in vivo.

Main Methods:

  • In vitro: MIT-001 tested on hydrogen peroxide-induced necrotic cell death in IEC-18 intestinal epithelial cells.
  • In vivo: Oral administration of MIT-001 to mice with DSS-induced colitis.
  • Assessed colon length, histological injury, HMGB1 expression, and pro-inflammatory cytokine levels (IL-1β, IL-12, MCP-1, TNF-α).

Main Results:

  • MIT-001 reduced necrotic cell death in intestinal epithelial cells in vitro.
  • In vivo, MIT-001 preserved colon length and reduced histological injury in DSS-treated mice.
  • MIT-001 significantly decreased HMGB1-positive cells and IL-1β expression in colonic tissue.

Conclusions:

  • MIT-001 ameliorates DSS-induced colitis, demonstrating therapeutic potential.
  • The drug's efficacy is associated with reduced HMGB1 and IL-1β.
  • Mitochondria-targeted anti-necrotic strategies warrant further investigation for IBD treatment.